Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aviva

This article was originally published in The Tan Sheet

Executive Summary

Functional food line for heart, bone and digestive health has been "well received" in Switzerland and Austria but is experiencing a "slow uptake" in the U.K., Novartis reports Aug. 21. Sluggish U.K. sales potentially could delay a U.S. debut of the line, tentatively slated for early 2001. The brand debuted in European test markets in late 1999 (1"The Tan Sheet" Nov. 22, 1999, p. 4). Novartis Consumer Health first-half worldwide sales of approximately $1.9 bil. marked an 8% increase in local currencies from the year-ago period. OTC sales increased 7% in local currencies, while both Medical Nutrition and Health & Functional Food division sales grew 9% in local currencies
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS091611

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel